Company Registration No. 07338890 (England and Wales)
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020
PAGES FOR FILING WITH REGISTRAR
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
3 - 8
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
BALANCE SHEET
AS AT
31 MARCH 2020
31 March 2020
- 1 -
2020
2019
Notes
£
£
£
£
Fixed assets
Tangible assets
3
108
289
Current assets
Debtors
4
72,430
64,620
Cash at bank and in hand
63,099
94,622
135,529
159,242
Creditors: amounts falling due within one year
5
(277,994)
(322,118)
Net current liabilities
(142,465)
(162,876)
Total assets less current liabilities
(142,357)
(162,587)
Capital and reserves
Called up share capital
6
159,000
159,000
Profit and loss reserves
(301,357)
(321,587)
Total equity
(142,357)
(162,587)
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.
true
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 31 July 2020 and are signed on its behalf by:
Mr S G Bhalerao
Mr V S Upadhye
Mr P P Mirajkar
Director
Director
Director
Company Registration No. 07338890
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2020
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 April 2018
159,000
(302,082)
(143,082)
Year ended 31 March 2019:
Loss and total comprehensive income for the year
-
(19,505)
(19,505)
Balance at 31 March 2019
159,000
(321,587)
(162,587)
Year ended 31 March 2020:
Profit and total comprehensive income for the year
-
20,230
20,230
Balance at 31 March 2020
159,000
(301,357)
(142,357)
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020
- 3 -
1
Accounting policies
Company information
Bioanalytical Technologies (UK) Limited is a
private
company
limited by shares
incorporated in England and Wales.
The registered office is
Orega, 3 Shortlands, Hammersmith, London, W6 8DA.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in
sterling
, which is the functional currency of the company.
Monetary a
mounts
in these financial statements are
rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
The financial statements show net current liabilities of £142,465 including an amount due to the parent
undertaking
in excess of this figure. The directors of the parent undertaking have indicated their willingness to support this
company by not seeking immediate recovery of the amount owed. The financial statements have therefore been
prepared on the going concern basis as the directors have a reasonable expectation that the company will continue
in operational existence for the foreseeable future taking into account the impact of Covid-19.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable
for
services provided in the normal course of business
, and
is shown net of VAT and other sales related taxes
.
The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.
1.4
Tangible fixed assets
Tangible fixed assets
are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Fixtures, fittings & equipment
33.3% Straight Line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and
is credited or charged to profit or loss
.
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2020
1
Accounting policies
(Continued)
- 4 -
1.5
Impairment of fixed assets
At each reporting
period
end date, the
company
reviews the carrying amounts of its tangible
assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company
estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit)
in
prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.6
Cash and cash equivalents
Cash and cash equivalents
are basic financial assets
and
include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.7
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset
, with
the net amounts presented in the financial statements
,
when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest
method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
Financial assets classified as receivable within one year are not amortised.
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2020
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from
fellow group companies and preference shares that are classified as debt, are
initially recognised at transaction price unless the arrangement constitutes a
financing transaction, where the debt instrument is measured at the present value of
the future
paymen
ts discounted at a market rate of interest.
Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective
interest rate method.
Trade creditors
are obligations to pay for goods or services that have been acquired
in the ordinary course of business from suppliers. A
m
ounts payable are classified as
current liabilities if payment is due within one year or less. If not, they are presented
as non-current liabilities. Trade creditors are recognised initially at transaction price
and subsequently measured at amortised cost using the effective interest method.
1.8
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.
1.9
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.10
Leases
Rentals payable under operating leases,
including
any lease incentives received, are charged to
profit or loss
on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease
s
asset are consumed.
1.11
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation
in the period
are included in profit or loss.
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2020
- 6 -
2
Employees
2020
2019
Number
Number
Total
1
2
3
Tangible fixed assets
Fixtures, fittings & equipment
£
Cost
At 1 April 2019 and 31 March 2020
1,573
Depreciation and impairment
At 1 April 2019
1,284
Depreciation charged in the year
181
At 31 March 2020
1,465
Carrying amount
At 31 March 2020
108
At 31 March 2019
289
4
Debtors
2020
2019
Amounts falling due within one year:
£
£
Trade debtors
72,430
62,156
Other debtors
-
2,464
72,430
64,620
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2020
- 7 -
5
Creditors: amounts falling due within one year
2020
2019
£
£
Amounts owed to group undertakings
185,036
242,054
Taxation and social security
53,662
40,110
Other creditors
39,296
39,954
277,994
322,118
6
Called up share capital
2020
2019
£
£
Ordinary share capital
Issued and fully paid
159,000 Ordinary shares of £1 each
159,000
159,000
159,000
159,000
7
Audit report information
As the income statement has been omitted from the filing copy of the financial statements
,
the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006
:
The auditor's report was unqualified.
We draw attention to note 1.2 in the financial statements, which indicates that the company has net current liabilities of £142,465. As stated in note 1.2 this net current liability, and the effect of the ongoing Covid-19 pandemic on this company and the parent company indicate that a material uncertainty exists, if the company does not earn sufficient profits in the near future, that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.
The senior statutory auditor was Alison Buckley.
The auditor was Mitchell Charlesworth LLP.
8
Related party transactions
At the year end the company owed it's parent company £
185,036
(201
9
: £2
42,054
).
BIOANALYTICAL TECHNOLOGIES (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2020
- 8 -
9
Parent company
The company is a wholly owned subsidiary of Bio-Analytical Technologies (India) Pvt. Limited which is registered in India.
The financial statements for Bio-Analytical Technologies (India) Pvt, Limited can be obtained from the following address:
B.A.T House
720/10 Plot No. 985
Navi Peth Off Lai Bahadur Shastri Road
Pune
411 030 India
2020-03-31
2019-04-01
false
31 July 2020
CCH Software
CCH Accounts Production 2020.200
No description of principal activity
This audit opinion is unqualified
Mr S G Bhalerao
Mr V S Upadhye
Mr P P Mirajkar
07338890
2019-04-01
2020-03-31
07338890
2020-03-31
07338890
2019-03-31
07338890
core:FurnitureFittings
2020-03-31
07338890
core:FurnitureFittings
2019-03-31
07338890
core:CurrentFinancialInstruments
core:WithinOneYear
2020-03-31
07338890
core:CurrentFinancialInstruments
core:WithinOneYear
2019-03-31
07338890
core:CurrentFinancialInstruments
2020-03-31
07338890
core:CurrentFinancialInstruments
2019-03-31
07338890
core:ShareCapital
2020-03-31
07338890
core:ShareCapital
2019-03-31
07338890
core:RetainedEarningsAccumulatedLosses
2020-03-31
07338890
core:RetainedEarningsAccumulatedLosses
2019-03-31
07338890
core:ShareCapital
core:RestatedAmount
2018-03-31
07338890
core:RetainedEarningsAccumulatedLosses
core:RestatedAmount
2018-03-31
07338890
core:RestatedAmount
2018-03-31
07338890
core:ShareCapitalOrdinaryShares
2020-03-31
07338890
core:ShareCapitalOrdinaryShares
2019-03-31
07338890
bus:Director2
2019-04-01
2020-03-31
07338890
bus:Director3
2019-04-01
2020-03-31
07338890
2018-04-01
2019-03-31
07338890
core:FurnitureFittings
2019-04-01
2020-03-31
07338890
core:FurnitureFittings
2019-03-31
07338890
core:WithinOneYear
2019-03-31
07338890
bus:OrdinaryShareClass1
2019-04-01
2020-03-31
07338890
bus:OrdinaryShareClass1
2020-03-31
07338890
bus:PrivateLimitedCompanyLtd
2019-04-01
2020-03-31
07338890
bus:SmallCompaniesRegimeForAccounts
2019-04-01
2020-03-31
07338890
bus:FRS102
2019-04-01
2020-03-31
07338890
bus:Audited
2019-04-01
2020-03-31
07338890
bus:Director1
2019-04-01
2020-03-31
07338890
bus:FullAccounts
2019-04-01
2020-03-31
xbrli:pure
xbrli:shares
iso4217:GBP